SOPHiA GENETICS (SOPH) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$7.41
+1.5% on the day
+62.5% over 12 months
52-week range $3.89 – $8.92
Share price and insider trades
SOPH closeInsider buyInsider sale
Bought, 12 months$99K
Sold, 12 months$5.1M
Insiders buying1
Insiders selling10
SOPHiA GENETICS insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $99K and 10 sold $5.1M of SOPH stock on the open market.
Get emailed when insiders cluster-buy stocks like SOPH
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SOPH insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $669K | 10 |
| Q3 2026 | — | 0 | $2.3M | 45 |
| Q2 2026 | $99K | 1 | $2.1M | 83 |
| Q1 2026 | — | 0 | $42K | 9 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit+$49KOn all tracked purchases +49.7%
Summary
Over the past 12 months, 1 SOPHiA GENETICS SA insider reported open-market purchases totaling $99K, while 10 insiders reported sales totaling $5.1M. 135 of 147 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | Jurgi CamblongChair | Sell Plan | 40,1723,395,650 held (−1%) | $8.13 | $327K | -8.8% | — |
| Oct 7SEC | Ross MukenCEO | Sell Plan | 9,838660,391 held (−1%) | $8.13 | $80K | -8.8% | — |
| Oct 7SEC | Philippe MenuChief Medical Officer | Sell Plan | 7,394200,993 held (−4%) | $8.13 | $60K | -8.8% | — |
| Oct 7SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 7,394545,493 held (−1%) | $8.12 | $60K | -8.8% | — |
| Oct 7SEC | Well Daan VanGeneral Counsel | Sell Plan | 6,168332,716 held (−2%) | $8.12 | $50K | -8.8% | — |
| Oct 7SEC | Abhimanyu VermaCTO | Sell Plan | 5,284166,887 held (−3%) | $8.12 | $43K | -8.8% | — |
| Oct 7SEC | Manuela ValenteChief People Officer | Sell Plan | 4,240206,210 held (−2%) | $8.13 | $34K | -8.9% | — |
| Oct 7SEC | George CardozaCFO | Sell Plan | 1,592306,726 held (−1%) | $8.10 | $13K | -8.5% | — |
| Oct 7SEC | Kevin PuylaertChief Sales Officer | Sell | 185147,763 held (−0%) | $8.06 | $1K | -8.1% | — |
| Oct 7SEC | Kevin PuylaertChief Sales Officer | Sell | 31147,732 held (−0%) | $7.92 | $246 | -6.4% | — |
| Sep 22SEC | George CardozaCFO | Sell Plan | 774308,318 held (−0%) | $8.33 | $6K | -11.0% | — |
| Sep 22SEC | Ross MukenCEO | Sell Plan | 422670,229 held (−0%) | $8.33 | $4K | -11.0% | — |
| Sep 16SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000208,387 held (−2%) | $7.88 | $39K | -6.0% | — |
| Sep 16SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 4,000552,887 held (−1%) | $7.88 | $32K | -6.0% | — |
| Sep 14SEC | Jurgi CamblongChair | Sell Plan | 8,5003,435,822 held (−0%) | $7.66 | $65K | -3.3% | — |
| Sep 14SEC | Well Daan VanGeneral Counsel | Sell Plan | 6,168338,884 held (−2%) | $7.63 | $47K | -2.9% | — |
| Sep 10SEC | Kathy L HibbsDirector | Sell Plan | 6,25096,992 held (−6%) | $8.13 | $51K | -8.9% | — |
| Aug 31SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 10,000556,887 held (−2%) | $8.91 | $89K | -16.8% | — |
| Aug 26SEC | Kathy L HibbsDirector | Sell Plan | 6,250103,242 held (−6%) | $8.68 | $54K | -14.6% | — |
| Aug 26SEC | Abhimanyu VermaCTO | Sell Plan | 5,000172,171 held (−3%) | $8.80 | $44K | -15.8% | — |
| Aug 26SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000213,387 held (−2%) | $8.68 | $43K | -14.6% | — |
| Aug 26SEC | Abhimanyu VermaCTO | Sell Plan | 5,000177,171 held (−3%) | $8.20 | $41K | -9.6% | — |
| Aug 21SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 10,000576,887 held (−2%) | $7.94 | $79K | -6.7% | — |
| Aug 21SEC | Manuela ValenteChief People Officer | Sell Plan | 10,000210,450 held (−5%) | $7.94 | $79K | -6.7% | — |
| Aug 21SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 5,408566,887 held (−1%) | $8.40 | $45K | -11.8% | — |
| Aug 21SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 4,592572,295 held (−1%) | $8.41 | $39K | -11.9% | — |
| Aug 14SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000218,387 held (−2%) | $7.52 | $38K | -1.5% | — |
| Aug 14SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 4,000586,887 held (−1%) | $7.52 | $30K | -1.5% | — |
| Aug 10SEC | Jurgi CamblongChair | Sell Plan | 20,0003,452,822 held (−1%) | $7.23 | $145K | +2.5% | — |
| Aug 10SEC | Jurgi CamblongChair | Sell Plan | 8,5003,444,322 held (−0%) | $7.61 | $65K | -2.6% | — |
| Aug 10SEC | Abhimanyu VermaCTO | Sell Plan | 5,000182,171 held (−3%) | $7.60 | $38K | -2.5% | — |
| Aug 7SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 10,000590,887 held (−2%) | $7.48 | $75K | -0.9% | — |
| Aug 7SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 7,000600,887 held (−1%) | $7.02 | $49K | +5.6% | — |
| Aug 7SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 3,000600,887 held (−0%) | $7.00 | $21K | +5.9% | — |
| Aug 5SEC | Jurgi CamblongChair | Sell Plan | 20,0003,472,822 held (−1%) | $6.92 | $138K | +7.1% | — |
| Aug 5SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 10,000600,887 held (−2%) | $6.92 | $69K | +7.1% | — |
| Aug 5SEC | Abhimanyu VermaCTO | Sell Plan | 5,000187,171 held (−3%) | $6.95 | $35K | +6.6% | — |
| Jul 28SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000223,387 held (−2%) | $5.66 | $28K | +30.9% | — |
| Jul 22SEC | Jurgi CamblongChair | Sell Plan | 20,0003,492,822 held (−1%) | $6.63 | $133K | +11.8% | — |
| Jul 22SEC | Jurgi CamblongChair | Sell Plan | 19,8003,512,822 held (−1%) | $6.32 | $125K | +17.2% | — |
| Jul 22SEC | Jurgi CamblongChair | Sell Plan | 4,5813,512,822 held (−0%) | $6.17 | $28K | +20.1% | — |
| Jul 14SEC | Jurgi CamblongChair | Sell Plan | 8,5003,532,622 held (−0%) | $5.62 | $48K | +31.9% | — |
| Jul 14SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000228,387 held (−2%) | $5.70 | $28K | +30.0% | — |
| Jul 14SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 4,000610,887 held (−1%) | $5.70 | $23K | +30.0% | — |
| Jul 8SEC | Jurgi CamblongChair | Sell Plan | 17,6853,541,122 held (−0%) | $5.28 | $93K | +40.3% | — |
| Jul 7SEC | Jurgi CamblongChair | Sell Plan | 22,4863,558,807 held (−1%) | $5.26 | $118K | +40.9% | — |
| Jul 7SEC | Ross MukenCEO | Sell Plan | 9,838670,651 held (−1%) | $5.22 | $51K | +42.0% | — |
| Jul 7SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 7,393614,887 held (−1%) | $5.17 | $38K | +43.3% | — |
| Jul 7SEC | Philippe MenuChief Medical Officer | Sell Plan | 7,393233,387 held (−3%) | $5.16 | $38K | +43.6% | — |
| Jul 7SEC | Abhimanyu VermaCTO | Sell Plan | 5,285192,171 held (−3%) | $5.10 | $27K | +45.3% | — |
| Jul 7SEC | Manuela ValenteChief People Officer | Sell Plan | 4,241210,450 held (−2%) | $5.05 | $21K | +46.7% | — |
| Jul 7SEC | George CardozaCFO | Sell Plan | 1,592309,092 held (−1%) | $5.29 | $8K | +40.1% | — |
| Jul 7SEC | Kevin PuylaertChief Sales Officer | Sell | 138148,026 held (−0%) | $5.03 | $694 | +47.3% | — |
| Jul 7SEC | Kevin PuylaertChief Sales Officer | Sell | 47147,979 held (−0%) | $5.03 | $236 | +47.3% | — |
| Jul 7SEC | Kevin PuylaertChief Sales Officer | Sell | 31147,948 held (−0%) | $5.09 | $158 | +45.6% | — |
| Jul 1SEC | Jurgi CamblongChair | Sell Plan | 45,4193,601,143 held (−1%) | $6.14 | $279K | +20.7% | — |
| Jul 1SEC | Jurgi CamblongChair | Sell Plan | 19,6503,581,493 held (−1%) | $6.02 | $118K | +23.1% | — |
| Jul 1SEC | Jurgi CamblongChair | Sell Plan | 18,0603,601,493 held (−0%) | $5.87 | $106K | +26.2% | — |
| Jul 1SEC | Jurgi CamblongChair | Sell Plan | 3503,601,143 held (−0%) | $6.00 | $2K | +23.5% | — |
| Jul 1SEC | Jurgi CamblongChair | Sell Plan | 2003,581,293 held (−0%) | $6.30 | $1K | +17.6% | — |
| Jun 29SEC | Jurgi CamblongCEO | Sell Plan | 31,9403,601,493 held (−1%) | $5.84 | $187K | +26.9% | — |
| Jun 29SEC | Jurgi CamblongCEO | Sell Plan | 18,1293,601,493 held (−1%) | $5.73 | $104K | +29.3% | — |
| Jun 29SEC | Jurgi CamblongCEO | Sell Plan | 1,3733,619,622 held (−0%) | $5.70 | $8K | +30.0% | — |
| Jun 26SEC | Abhimanyu VermaCTO | Sell Plan | 6,944197,456 held (−3%) | $5.51 | $38K | +34.5% | — |
| Jun 26SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000240,780 held (−2%) | $5.50 | $28K | +34.7% | — |
| Jun 23SEC | George CardozaCFO | Sell Plan | 774310,684 held (−0%) | $5.38 | $4K | +37.7% | — |
| Jun 23SEC | Ross MukenPresident | Sell Plan | 422680,489 held (−0%) | $5.38 | $2K | +37.7% | — |
| Jun 17SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 4,000622,280 held (−1%) | $5.01 | $20K | +47.9% | — |
| Jun 15SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000245,780 held (−2%) | $4.95 | $25K | +49.7% | — |
| Jun 11SEC | Jurgi CamblongCEO | Sell Plan | 8,5003,620,995 held (−0%) | $5.24 | $45K | +41.4% | — |
| Jun 5SEC | George CardozaCFO | Buy | 20,000311,458 held (+7%) | $4.95 | $99K | +49.7% | — |
| Jun 1SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000250,780 held (−2%) | $4.95 | $25K | +49.7% | — |
| May 20SEC | Jurgi CamblongCEO | Sell Plan | 4,4863,629,495 held (−0%) | $4.60 | $21K | +61.1% | — |
| May 20SEC | Ross MukenPresident | Sell Plan | 761680,911 held (−0%) | $4.60 | $4K | +61.1% | — |
| May 20SEC | Well Daan VanGeneral Counsel | Sell Plan | 684345,052 held (−0%) | $4.60 | $3K | +61.1% | — |
| May 20SEC | Philippe MenuChief Medical Officer | Sell Plan | 608255,780 held (−0%) | $4.61 | $3K | +60.7% | — |
| May 20SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 608626,280 held (−0%) | $4.60 | $3K | +61.1% | — |
| May 20SEC | Manuela ValenteChief People Officer | Sell Plan | 380214,691 held (−0%) | $4.60 | $2K | +61.1% | — |
| May 20SEC | Kevin PuylaertChief Sales Officer | Sell | 33148,164 held (−0%) | $4.54 | $150 | +63.2% | — |
| May 14SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 4,000626,888 held (−1%) | $4.54 | $18K | +63.2% | — |
| May 13SEC | Kathy L HibbsDirector | Sell Plan | 7,50889,768 held (−8%) | $4.67 | $35K | +58.7% | — |
| May 13SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000256,388 held (−2%) | $4.67 | $23K | +58.7% | — |
| May 12SEC | Jurgi CamblongCEO | Sell Plan | 8,5003,633,981 held (−0%) | $5.09 | $43K | +45.6% | — |
| Apr 28SEC | Philippe MenuChief Medical Officer | Sell Plan | 5,000261,388 held (−2%) | $4.82 | $24K | +53.7% | — |
| Apr 21SEC | Jurgi CamblongCEO | Sell Plan | 4,4863,642,481 held (−0%) | $5.21 | $23K | +42.2% | — |
| Apr 21SEC | Ross MukenPresident | Sell Plan | 760681,672 held (−0%) | $5.20 | $4K | +42.5% | — |
| Apr 21SEC | Well Daan VanGeneral Counsel | Sell Plan | 684345,736 held (−0%) | $5.20 | $4K | +42.5% | — |
| Apr 21SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 608630,888 held (−0%) | $5.21 | $3K | +42.2% | — |
| Apr 21SEC | Philippe MenuChief Medical Officer | Sell Plan | 608266,388 held (−0%) | $5.20 | $3K | +42.5% | — |
| Apr 21SEC | Manuela ValenteChief People Officer | Sell Plan | 380215,071 held (−0%) | $5.20 | $2K | +42.5% | — |
| Apr 21SEC | Kevin PuylaertChief Sales Officer | Sell | 33148,197 held (−0%) | $5.08 | $168 | +45.9% | — |
| Apr 16SEC | Jurgi CamblongCEO | Sell Plan | 43,1293,664,440 held (−1%) | $4.96 | $214K | +49.4% | — |
| Apr 16SEC | Jurgi CamblongCEO | Sell Plan | 17,4733,646,967 held (−0%) | $5.00 | $87K | +48.2% | — |
| Apr 16SEC | Ross MukenPresident | Sell Plan | 2,800682,432 held (−0%) | $4.96 | $14K | +49.4% | — |
| Apr 16SEC | Philippe MenuChief Medical Officer | Sell Plan | 1,600266,996 held (−1%) | $4.96 | $8K | +49.4% | — |
| Apr 16SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 600631,496 held (−0%) | $4.97 | $3K | +49.1% | — |
| Apr 14SEC | Jurgi CamblongCEO | Sell Plan | 8,5003,715,700 held (−0%) | $4.72 | $40K | +57.0% | — |
| Apr 14SEC | Ross MukenPresident | Sell Plan | 4,442685,232 held (−1%) | $4.77 | $21K | +55.3% | — |
| Apr 14SEC | Jurgi CamblongCEO | Sell Plan | 4,3993,707,569 held (−0%) | $4.76 | $21K | +55.7% | — |
| Apr 14SEC | Jurgi CamblongCEO | Sell Plan | 3,7323,711,968 held (−0%) | $4.72 | $18K | +57.0% | — |
| Apr 14SEC | Philippe MenuChief Medical Officer | Sell Plan | 3,725272,996 held (−1%) | $4.68 | $17K | +58.3% | — |
| Apr 14SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 3,706636,510 held (−1%) | $4.68 | $17K | +58.3% | — |
| Apr 14SEC | Ross MukenPresident | Sell Plan | 3,687689,674 held (−1%) | $4.69 | $17K | +58.0% | — |
| Apr 14SEC | Philippe MenuChief Medical Officer | Sell Plan | 3,400268,596 held (−1%) | $4.76 | $16K | +55.7% | — |
| Apr 14SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 3,400632,096 held (−1%) | $4.76 | $16K | +55.7% | — |
| Apr 14SEC | Well Daan VanGeneral Counsel | Sell Plan | 2,400346,420 held (−1%) | $4.67 | $11K | +58.7% | — |
| Apr 14SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 1,014635,496 held (−0%) | $4.76 | $5K | +55.7% | — |
| Apr 14SEC | Philippe MenuChief Medical Officer | Sell Plan | 1,000271,996 held (−0%) | $4.76 | $5K | +55.7% | — |
| Apr 10SEC | Manuela ValenteChief People Officer | Sell Plan | 3,824215,451 held (−2%) | $4.85 | $19K | +52.8% | — |
| Apr 10SEC | Well Daan VanGeneral Counsel | Sell Plan | 2,861350,808 held (−1%) | $4.85 | $14K | +52.8% | — |
| Apr 10SEC | Jurgi CamblongCEO | Sell Plan | 2,8003,726,150 held (−0%) | $4.84 | $14K | +53.1% | — |
| Apr 10SEC | Philippe MenuChief Medical Officer | Sell Plan | 2,800278,652 held (−1%) | $4.84 | $14K | +53.1% | — |
| Apr 10SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 2,800642,152 held (−0%) | $4.84 | $14K | +53.1% | — |
| Apr 10SEC | Ross MukenPresident | Sell Plan | 2,786695,311 held (−0%) | $4.84 | $13K | +53.1% | — |
| Apr 10SEC | Well Daan VanGeneral Counsel | Sell Plan | 1,988348,820 held (−1%) | $4.74 | $9K | +56.3% | — |
| Apr 10SEC | Jurgi CamblongCEO | Sell Plan | 1,9503,724,200 held (−0%) | $4.74 | $9K | +56.3% | — |
| Apr 10SEC | Ross MukenPresident | Sell Plan | 1,950693,361 held (−0%) | $4.74 | $9K | +56.3% | — |
| Apr 10SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 1,936640,216 held (−0%) | $4.74 | $9K | +56.3% | — |
| Apr 10SEC | Philippe MenuChief Medical Officer | Sell Plan | 1,931276,721 held (−1%) | $4.74 | $9K | +56.3% | — |
| Apr 10SEC | George CardozaCFO | Sell Plan | 1,403291,458 held (−0%) | $4.85 | $7K | +52.8% | — |
| Apr 8SEC | Well Daan VanGeneral Counsel | Sell Plan | 2,705356,069 held (−1%) | $4.86 | $13K | +52.5% | — |
| Apr 8SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 2,700647,352 held (−0%) | $4.85 | $13K | +52.8% | — |
| Apr 8SEC | Philippe MenuChief Medical Officer | Sell Plan | 2,700283,852 held (−1%) | $4.85 | $13K | +52.8% | — |
| Apr 8SEC | Jurgi CamblongCEO | Sell Plan | 2,6003,731,450 held (−0%) | $4.85 | $13K | +52.8% | — |
| Apr 8SEC | Ross MukenPresident | Sell Plan | 2,600700,521 held (−0%) | $4.85 | $13K | +52.8% | — |
| Apr 8SEC | Manuela ValenteChief People Officer | Sell Plan | 2,597221,651 held (−1%) | $4.85 | $13K | +52.8% | — |
| Apr 8SEC | Abhimanyu VermaCTO | Sell Plan | 2,519205,430 held (−1%) | $4.86 | $12K | +52.5% | — |
| Apr 8SEC | George CardozaCFO | Sell Plan | 2,520295,274 held (−1%) | $4.85 | $12K | +52.8% | — |
| Apr 8SEC | Jurgi CamblongCEO | Sell Plan | 2,5003,728,950 held (−0%) | $4.86 | $12K | +52.5% | — |
| Apr 8SEC | Ross MukenPresident | Sell Plan | 2,424698,097 held (−0%) | $4.87 | $12K | +52.2% | — |
| Apr 8SEC | George CardozaCFO | Sell Plan | 2,413292,861 held (−1%) | $4.88 | $12K | +51.8% | — |
| Apr 8SEC | Well Daan VanGeneral Counsel | Sell Plan | 2,400353,669 held (−1%) | $4.87 | $12K | +52.2% | — |
| Apr 8SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 2,400644,952 held (−0%) | $4.87 | $12K | +52.2% | — |
| Apr 8SEC | Philippe MenuChief Medical Officer | Sell Plan | 2,400281,452 held (−1%) | $4.87 | $12K | +52.2% | — |
| Apr 8SEC | Manuela ValenteChief People Officer | Sell Plan | 2,376219,275 held (−1%) | $4.87 | $12K | +52.2% | — |
| Apr 8SEC | Abhimanyu VermaCTO | Sell Plan | 1,030204,400 held (−1%) | $4.87 | $5K | +52.2% | — |
| Apr 8SEC | Kevin PuylaertChief Sales Officer | Sell | 548148,306 held (−0%) | $4.86 | $3K | +52.5% | — |
| Apr 8SEC | Kevin PuylaertChief Sales Officer | Sell | 46148,260 held (−0%) | $4.86 | $224 | +52.5% | — |
| Apr 8SEC | Kevin PuylaertChief Sales Officer | Sell | 30148,230 held (−0%) | $4.83 | $145 | +53.4% | — |
| Apr 1SEC | Kevin PuylaertChief Sales Officer | Sell | 392,383 held (−0%) | $4.71 | $14 | +57.3% | — |
| Mar 20SEC | Jurgi CamblongCEO | Sell Plan | 4,4863,302,839 held (−0%) | $4.77 | $21K | +55.3% | — |
| Mar 20SEC | Ross MukenPresident | Sell Plan | 1,183271,910 held (−0%) | $4.79 | $6K | +54.7% | — |
| Mar 20SEC | George CardozaCFO | Sell Plan | 774184,858 held (−0%) | $4.79 | $4K | +54.7% | — |
| Mar 20SEC | Well Daan VanGeneral Counsel | Sell Plan | 684261,238 held (−0%) | $4.79 | $3K | +54.7% | — |
| Mar 20SEC | Philippe MenuChief Medical Officer | Sell Plan | 608173,616 held (−0%) | $4.79 | $3K | +54.7% | — |
| Mar 20SEC | Zhenyu XuChief Scientific Officer | Sell Plan | 608537,116 held (−0%) | $4.78 | $3K | +55.0% | — |
| Mar 20SEC | Manuela ValenteChief People Officer | Sell Plan | 380152,379 held (−0%) | $4.79 | $2K | +54.7% | — |
| Mar 20SEC | Kevin PuylaertChief Sales Officer | Sell | 3392,386 held (−0%) | $4.76 | $157 | +55.7% | — |
Insiders at SOPHiA GENETICS SA
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Jurgi CamblongChair | — | $2.7M | Oct 7, 2026 | — |
| Zhenyu XuChief Scientific Officer | — | $785K | Oct 7, 2026 | — |
| Philippe MenuChief Medical Officer | — | $503K | Oct 7, 2026 | — |
| George CardozaCFO | $99K | $66K | Oct 7, 2026 | — |
| Abhimanyu VermaCTO | — | $283K | Oct 7, 2026 | — |
| Ross MukenCEO | — | $250K | Oct 7, 2026 | — |
| Manuela ValenteChief People Officer | — | $184K | Oct 7, 2026 | — |
| Well Daan VanGeneral Counsel | — | $166K | Oct 7, 2026 | — |
| Kathy L HibbsDirector | — | $140K | Sep 10, 2026 | — |
| Kevin PuylaertChief Sales Officer | — | $6K | Oct 7, 2026 | — |
SOPH stock: common questions
Are SOPHiA GENETICS SA insiders buying SOPH stock?
In the past 12 months, 1 insiders reported open-market purchases of SOPH worth $99K. The latest was CFO George Cardoza bought $99K of SOPH at $4.95 — first open-market purchase in our records.
Are SOPHiA GENETICS SA insiders selling SOPH stock?
10 insiders reported sales worth $5.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SOPH's 52-week range?
Over the past year SOPH has traded between $3.89 and $8.92. It last closed at $7.41 on Oct 9, 2026.